Market closed

Arrowhead Pharmaceuticals/$ARWR

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.

Ticker

$ARWR
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Pasadena, United States

Employees

609
Website
arrowheadpharma.com

ARWR Metrics

BasicAdvanced
$2.4B
-
-$5.00
0.93
-

$2.4B

0.93

$36.72

$17.05

1.8M

6.741

6.567

442.561

445.881

-18.58%

-39.43%

-254.98%

637.882

12.68

13.3

-3.748

-98.53%

160.27%

-70.50%

54.39%

What the Analysts think about ARWR

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Arrowhead Pharmaceuticals stock.

ARWR Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ARWR Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ARWR News

AllArticlesVideos
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

Business Wire·3 weeks ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Business Wire·4 weeks ago
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity

Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ARWR

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Arrowhead Pharmaceuticals stock?

Arrowhead Pharmaceuticals (ARWR) has a market cap of $2.4B as of January 15, 2025.

What is the P/E ratio for Arrowhead Pharmaceuticals stock?

The price to earnings (P/E) ratio for Arrowhead Pharmaceuticals (ARWR) stock is 0 as of January 15, 2025.

Does Arrowhead Pharmaceuticals stock pay dividends?

No, Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Arrowhead Pharmaceuticals dividend payment date?

Arrowhead Pharmaceuticals (ARWR) stock does not pay dividends to its shareholders.

What is the beta indicator for Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (ARWR) has a beta rating of 0.93. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.